However, similar to other chemotherapeutic agents, TOP2-targeting drugs are only partially selective for tumour cells, resulting in unwanted toxicity in normal tissues and in therapy-associated chromosome translocations and secondary leukemias [6]–[14]. The gene discussed is TOP2A; the disease is neoplasm.